Literature DB >> 19891662

Endothelium modulates vasoconstrictor response to prostaglandin I2 in rat mesenteric resistance arteries: interaction between EP1 and TP receptors.

F E Xavier1, J Blanco-Rivero, M Ferrer, G Balfagón.   

Abstract

BACKGROUND AND
PURPOSE: Prostacyclin (PGI(2)) is usually described as an endothelium-derived vasodilator, but it can also induce vasoconstriction. We studied the vasomotor responses to PGI(2) in resistance arteries and the role of thromboxane (TP) and prostaglandin E(2) (EP) receptors in this effect. EXPERIMENTAL APPROACH: Mesenteric resistance arteries were obtained from Sprague-Dawley rats. Vasomotion to PGI(2) was studied in segments of these arteries with and without endothelium and in presence of the nitric oxide (NO) synthase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME), the potassium channel blockers apamin plus charybdotoxin, the non-selective EP receptor antagonist AH6809, the selective TP receptor antagonist SQ29548 or the EP(1) receptor antagonist SC19220. PGI(2)-induced NO release was analysed in the absence or presence of SQ29548, AH6809 or SC19220. KEY
RESULTS: PGI(2) caused contractions in arterial segments that were increased by endothelium removal, L-NAME or L-NAME plus apamin plus charybdotoxin and abolished by SQ29548. In segments with endothelium, AH6809 or SC19220 almost abolished the contractions to PGI(2); this effect was prevented by L-NAME, L-NAME plus apamin plus charybdotoxin or by endothelium removal. PGI(2) induced NO release that was inhibited by the prostacyclin receptor (IP receptor) antagonist, RO1138452, and increased by SQ29548, SC19220 and AH6809. The increase in NO release induced by these separate drugs was inhibited by RO1138452. CONCLUSIONS AND IMPLICATIONS: PGI(2) activated the TP receptor in mesenteric resistance arteries and produced vasoconstriction, which the endothelium modulated through TP and EP(1) receptors. PGI(2) also released endothelium-derived hyperpolarizing factor and, through IP receptor activation, induced NO release, which in turn, was antagonized by TP and EP(1) receptor activation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891662      PMCID: PMC2801220          DOI: 10.1111/j.1476-5381.2009.00459.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

Review 1.  Prostanoid receptors: subtypes and signaling.

Authors:  R M Breyer; C K Bagdassarian; S A Myers; M D Breyer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

2.  The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

Authors:  M Abramovitz; M Adam; Y Boie; M Carrière; D Denis; C Godbout; S Lamontagne; C Rochette; N Sawyer; N M Tremblay; M Belley; M Gallant; C Dufresne; Y Gareau; R Ruel; H Juteau; M Labelle; N Ouimet; K M Metters
Journal:  Biochim Biophys Acta       Date:  2000-01-17

3.  Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration.

Authors:  Anthony W Ashton; J Anthony Ware
Journal:  Circ Res       Date:  2004-07-08       Impact factor: 17.367

4.  Guide to Receptors and Channels (GRAC), 3rd edition.

Authors:  S P H Alexander; A Mathie; J A Peters
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

5.  Differential effects of prostacyclin and iloprost in the isolated carotid artery of the guinea-pig.

Authors:  C Corriu; M Félétou; G Edwards; A H Weston; P M Vanhoutte
Journal:  Eur J Pharmacol       Date:  2001-08-24       Impact factor: 4.432

6.  The role of prostaglandin E and thromboxane-prostanoid receptors in the response to prostaglandin E2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rats.

Authors:  Eva H C Tang; Boye L Jensen; Ole Skott; George P H Leung; Michel Feletou; Ricky Y K Man; Paul M Vanhoutte
Journal:  Cardiovasc Res       Date:  2007-12-18       Impact factor: 10.787

7.  Interactions of adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: in vivo and in vitro studies.

Authors:  Clare J Ray; Mark R Abbas; Andrew M Coney; Janice M Marshall
Journal:  J Physiol       Date:  2002-10-01       Impact factor: 5.182

8.  Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin.

Authors:  F E Xavier; R Aras-López; I Arroyo-Villa; L del Campo; M Salaices; L V Rossoni; M Ferrer; G Balfagón
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

9.  Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.

Authors:  S Moncada; E A Higgs; J R Vane
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

Review 10.  Potassium and potassium clouds in endothelium-dependent hyperpolarizations.

Authors:  Gillian Edwards; Arthur H Weston
Journal:  Pharmacol Res       Date:  2004-06       Impact factor: 7.658

View more
  9 in total

1.  Apolipoprotein E favours the blunting by high-fat diet of prostacyclin receptor activation in the mouse aorta.

Authors:  Yanhua Cheng; Paul M Vanhoutte; Susan W S Leung
Journal:  Br J Pharmacol       Date:  2018-07-22       Impact factor: 8.739

2.  Effect of age and COX-2-derived prostanoids on the progression of adult vascular dysfunction in the offspring of diabetic rats.

Authors:  F E Ramos-Alves; D B de Queiroz; J Santos-Rocha; G P Duarte; F E Xavier
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 3.  Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.

Authors:  Batoule H Majed; Raouf A Khalil
Journal:  Pharmacol Rev       Date:  2012-06-07       Impact factor: 25.468

4.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

5.  Hypersensitivity to thromboxane receptor mediated cerebral vasomotion and CBF oscillations during acute NO-deficiency in rats.

Authors:  Béla Horváth; Gábor Lenzsér; Balázs Benyó; Tamás Németh; Rita Benko; András Iring; Péter Hermán; Katalin Komjáti; Zsombor Lacza; Péter Sándor; Zoltán Benyó
Journal:  PLoS One       Date:  2010-12-31       Impact factor: 3.240

6.  Role of E-type prostaglandin receptor EP3 in the vasoconstrictor activity evoked by prostacyclin in thromboxane-prostanoid receptor deficient mice.

Authors:  Zhenhua Li; Yingzhan Zhang; Bin Liu; Wenhong Luo; Hui Li; Yingbi Zhou
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

7.  Increased role of E prostanoid receptor-3 in prostacyclin-evoked contractile activity of spontaneously hypertensive rat mesenteric resistance arteries.

Authors:  Bin Liu; Mengyi Zhan; Yingzhan Zhang; Hui Li; Xiangzhong Wu; Fengfeng Zhuang; Wenhong Luo; Yingbi Zhou
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

8.  Chronic Low-Level Lead Exposure Increases Mesenteric Vascular Reactivity: Role of Cyclooxygenase-2-Derived Prostanoids.

Authors:  Maylla Ronacher Simões; Bruna Fernandes Azevedo; María Jesús Alonso; Mercedes Salaices; Dalton Valentim Vassallo
Journal:  Front Physiol       Date:  2021-01-07       Impact factor: 4.566

9.  Flaxseed oil increases aortic reactivity to phenylephrine through reactive oxygen species and the cyclooxygenase-2 pathway in rats.

Authors:  Dieli Oliveira Nunes; Camila Cruz Pereira Almenara; Gilson Brás Broseghini-Filho; Marito Afonso Sousa Costa Silva; Ivanita Stefanon; Dalton V Vassallo; Alessandra S Padilha
Journal:  Lipids Health Dis       Date:  2014-07-03       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.